Checkpoint Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Checkpoint Therapeutics

07/05/2021 17:42

* Checkpoint Therapeutics Inc  CKPT.OQ  reported a quarterly
adjusted loss of 9 cents​​ per share for the quarter ended
in March. The mean expectation of four analysts for the quarter
was for a loss of 10 cents per share.
* Revenue fell 93% to $68.00 thousand from a year ago​; 
analysts expected $142.50 thousand.
* Checkpoint Therapeutics Inc's reported EPS for the quarter was
a loss of 9 cents​.
* The mean earnings estimate of analysts had fallen by
about 23.5% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Checkpoint Therapeutics Inc shares had fallen by 24.8% this
quarter and lost 10.9% so far this year.
* The company reported a quarterly loss of $6.51 million.
* Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $16.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 7 at 04:42 p.m. GMT. ​All
figures in US Dollars.​